Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Generated: March 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,534,527

« Back to Dashboard

Title: Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen
Abstract:The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
Inventor(s): Black; Larry J. (Indianapolis, IN), Cullinan; George J. (Trafalgar, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Apr 14, 1995
Application Number:08/422,096
Claims:1. A pharmaceutical formulation comprising an effective amount of a compound of formula I ##STR11## wherein X is a bond, CH.sub.2, or CH.sub.2 CH.sub.2 ;

R and R.sup.1, independently, are hydrogen, hydroxyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -acyloxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.2 -C.sub.6 -acyloxy, R.sup.3 -substituted aryloxy, R.sup.3 -substituted aroyloxy, R.sup.4 -substituted carbonyloxy, chloro, or bromo;

R.sup.2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;

R.sup.3 is C.sub.1 -C.sub.3 -alkyl, C.sub.1-C.sub.3 -alkoxy, hydrogen, or halo; and

R.sup.4 is C.sub.1 -C.sub.6 -alkoxy or aryloxy; or

a pharmaceutically acceptable salt thereof; estrogen and

a pharmaceutically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.